Bioasis Technologies Inc.

Bioasis Technologies to meet with FDA June 2019 on it xB3 platform technology

Bioasis Technologies Inc. (OTCQB:BIOAF) (TSX.V:BTI) Director, President & CEO Dr. Mark Day sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The Connecticut based biopharmaceutical company is developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.

Quick facts: Bioasis Technologies Inc.

Price: $0.19

Market Cap: $12.31 m


e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma...

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments. He also provided some insight into recent tie-ups with Denmark’s...

4 days, 2 hours ago

2 min read